Overview

A calf thymus extract used in Russian clinical practice for decades, and heavily promoted in Western longevity circles on the strength of a long-term study reporting reduced mortality in elderly subjects. Independent replication does not exist.

Limited or non-US approvalRegistered in Russia; unapproved elsewhere.

At a glance

Regulatory status	Registered in Russia as an immunomodulator. Not approved in the US, EU or UK.
Drug class	Polypeptide complex extracted from calf thymus — a mixture, not a single molecule
Route	Intramuscular
Half-life	Not applicable — heterogeneous mixture
Evidence rating	2/5 Limited Evidence rating 2 out of 5: Limited Preclinical work plus scattered human reports, uncontrolled use, or negative trials.
Studied in	Russian clinical studies in immunodeficiency and post-surgical infection; a long-term gerontology cohort study reporting mortality reduction in elderly participants.

How it works

Proposed to restore T-lymphocyte differentiation and normalise the CD4/CD8 ratio in immunodeficient states. As an undefined extract, the active constituents are not fully characterised, which limits mechanistic reasoning.

Evidence base

Rated 2 of 5 — Limited. Preclinical work plus scattered human reports, uncontrolled use, or negative trials.

Single-tradition evidence base with extraordinary longevity claims and no external replication.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

Reported immune restoration Preliminary

Russian studies describe normalisation of lymphocyte subsets in immunodepressed patients.
Long-term mortality signal Preliminary

A multi-year cohort study reported reduced mortality in treated elderly subjects. The study design and independence are significant caveats.
Long clinical use history Preliminary

Decades of use in Russian practice without prominent safety signals reported.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

Undefined composition Serious

An extract rather than a defined molecule, so batch consistency and mechanism attribution are both uncertain.
No independent replication Serious

The evidence base traces almost entirely to one research tradition and has not been reproduced elsewhere.
Bovine biological source Moderate evidence

Theoretical transmissible agent concerns and hypersensitivity risk from animal-derived protein.
Autoimmune and transplant contraindications Serious

Immune stimulation is inappropriate in autoimmune disease and after transplant.
Unregulated in the West Serious

Imported product has no quality assurance.

Who should avoid it

Autoimmune disease
Organ transplant recipients
Pregnancy
Known bovine protein allergy

If used under medical supervision, monitor

CBC with differential and lymphocyte subsets if used clinically

Commonly confused with

These mix-ups cause real harm — two products sold under one name, or two molecules whose effects run in opposite directions.

Thymosin Alpha-1 Limited Approval Evidence 4/5

Thymosin alpha-1 is a single defined 28-amino-acid peptide approved in more than 30 countries with randomized hepatitis trials behind it. Thymalin is an undefined bovine extract registered only in Russia.

Compare side by side

Regulatory & legal status

Registered in Russia; unapproved elsewhere.

Infographic

Thymalin — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

immunethymiclongevityRussia-approvedextract

Related peptides in Immune & Anti-inflammatory

Terms used on this page

Reproducibility and Replication: Reproducibility is obtaining the same result from the same data and analysis, while replication is obtaining a consistent result from new data, and only the second shows the finding is real.
Thymic Peptide: Thymic peptides are small peptides originally isolated from thymus tissue and proposed as immune-regulating hormones; only thymosin alpha-1 has meaningful clinical use, and it is not FDA-approved.
Cohort Study: A cohort study follows groups defined by exposure forward to their outcomes, allowing incidence and risk to be estimated directly but leaving treatment assignment to the world rather than to chance.
Safety Signal Detection: Safety signal detection is the statistical and clinical screening of adverse event databases for drug-event pairs reported more often than the rest of the data would predict.
Hypersensitivity Reaction: A hypersensitivity reaction is an immune response to a drug that injures the host, classified by the Gell and Coombs types from immediate IgE-mediated events to delayed T-cell-mediated ones.
Autoimmunity: Autoimmunity is an adaptive immune response directed at self, arising when central or peripheral tolerance fails, and it counts as disease only when that response produces demonstrable tissue injury.

This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.